Saturday 17 October 2026
Export XBIT’s income statement to Excel — free account
XBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.
2.12
0.04
−1.85%
Follow XBIT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (29.94%) | (25.93%) | (28.23%) | (16.23%) |
+8 more TTM periods Free account |
|
| (28.90%) | (24.97%) | (26.08%) | (15.25%) | ||
ROIC |
(159.18%) | (154.70%) | (235.17%) | (109.96%) | |
Return on Tangible Assets |
(34.64%) | (29.35%) | (32.04%) | (17.27%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.33) | (1.38) | (1.32) | (0.78) | |
Free Cash Flow |
(40.69) | (42.17) | (40.21) | (23.85) | |
Capital Expenditures |
— | — | (0.29) | (0.34) | |
| Other line items | |||||
Cash ROIC |
(17.10%) | (16.84%) | (15.12%) | (7.58%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 1.05 | 0.88 | 0.81 | |
Depreciation/Fixed assets |
0.06 | 0.07 | 0.07 | 0.07 | |
Capex/Depreciation |
0.00 | 0.00 | (0.17) | (0.19) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.38) | (1.31) | (0.77) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates